Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bilr 355. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 8/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.32 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bilr 355 SCHEMBL29399723 | 1.00 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| Bilr 355 SCHEMBL5080040 | 1.00 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| Bilr 355 SCHEMBL5247366 | 0.99 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL14383887 | 0.94 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL5744506 | 0.94 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL5211840 | 0.93 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19CYP1A2BRD4 | |
| SCHEMBL5745210 | 0.89 | CYP2C9 (0.52) | CYP3A4CYP2C9CYP2C19CYP1A2GPR84 | |
| SCHEMBL5768478 | 0.88 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19CYP1A2GPR84 | |
| SCHEMBL5743230 | 0.88 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19CYP1A2GPR84 | |
| SCHEMBL5747266 | 0.87 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19CYP1A2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069698-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | UNIV NEBRASKA (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4234561-B1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | UNIV NEBRASKA (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250099477-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2025-03-27 | — | — | US | disclosed |
| EP-4527463-A2 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS | VIIV Healthcare Company (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12257306-B2 | Antiviral prodrugs and nanoformulations thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025030072-A1 | LIPID NANOPARTICLES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| US-12168013-B2 | Antiviral prodrugs and nanoformulations thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2024-08-29 | — | — | US | disclosed |
| US-20220211716-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-07-07 | — | — | US | disclosed |
| US-20220194990-A1 | VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-06-23 | — | — | US | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220175936-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-06-09 | — | — | US | disclosed |
| US-11311547-B2 | Antiviral prodrugs and nanoformulations thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311545-B2 | Compositions and methods for the delivery of therapeutics | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2022-04-14 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | CIPLA LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | CYP3A4 2420/4885CYP2C9 2655/4885CYP2C19 1649/4885 |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | PAICS, HAVCR2, THPO | CYP3A4 69/4885CYP2C9 240/4885CYP2C19 56/4885 |
| US-12257306-B2 | Antiviral prodrugs and nanoformulations thereof | TYMP, PNP, SLC29A1 | CYP3A4 16/4885CYP2C9 218/4885CYP2C19 83/4885 |
| US-20220211716-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | TYMP, PNP, SLC29A1 | CYP3A4 16/4885CYP2C9 218/4885CYP2C19 83/4885 |
| US-12168013-B2 | Antiviral prodrugs and nanoformulations thereof | TYMP, PNP, SLC29A1 | CYP3A4 16/4885CYP2C9 218/4885CYP2C19 83/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | CYP3A4 2420/4885CYP2C9 2655/4885CYP2C19 1649/4885 |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | CYP3A4 69/4885CYP2C9 240/4885CYP2C19 56/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CYP3A4 64/4885CYP2C9 56/4885CYP2C19 68/4885 |
| US-20220175936-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | TYMP, PNP, SLC29A1 | CYP3A4 16/4885CYP2C9 218/4885CYP2C19 83/4885 |
| US-20250099477-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | TYMP, PNP, SLC29A1 | CYP3A4 16/4885CYP2C9 218/4885CYP2C19 83/4885 |
| US-11311547-B2 | Antiviral prodrugs and nanoformulations thereof | TYMP, PNP, SLC29A1 | CYP3A4 16/4885CYP2C9 218/4885CYP2C19 83/4885 |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | CYP3A4 69/4885CYP2C9 240/4885CYP2C19 56/4885 |
| US-11311545-B2 | Compositions and methods for the delivery of therapeutics | HAVCR2, MTREX, MAVS | CYP3A4 4604/4885CYP2C9 4525/4885CYP2C19 4318/4885 |
| US-20260069698-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | MAP2K6, MAP2K7, CDK8 | CYP3A4 152/4885CYP2C9 284/4885CYP2C19 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.